Vanda Pharmaceuticals (VNDA) surges 20% in premarket trading after Cycle Pharmaceuticals reaffirms $8/share all cash offer in ...

Cycle Pharmaceuticals Ltd ("Cycle"), a dynamic leader in developing rare disease therapies, today reaffirmed its proposal to ...

Vanda Pharmaceuticals on Monday rejected UK-based Cycle Pharmaceuticals' second takeover proposal, which values the drugmaker ...

The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s ...

Cycle’s second unsuccessful takeover bid comes on the heels of the FDA denying approval for Vanda’s tradipitant, which was ...

Cycle Pharmaceuticals reaffirmed its proposal to acquire all of the issued and outstanding shares of Vanda Pharmaceuticals ...

Update 11:15am: Adds Vanda response, updates shares. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped 11% after Cycle Pharmaceuticals reaffirmed its $8/share all cash offer for the company. "Cycle is ...

Vanda Pharmaceuticals rejected a second acquisition proposal from Cycle Group Holdings, saying terms are economically identical to a previously rejected indication of interest and that it ...

Shares of Vanda Pharmaceuticals jumped after Cycle Pharmaceuticals reaffirmed its proposal to buy the company for $8 a share. The stock was up 18% at $5.22 in early trading. Shares have gained 24% ...

Vanda Pharmaceuticals Inc. (VNDA) confirmed on Monday that it received a second unsolicited, non-binding proposal from Cycle Group ...

On Monday, Vanda Pharmaceuticals Inc. (VNDA) stock saw a modest uptick, ending the day at $4.81 which represents a slight increase of $0.37 or 8.33% from the prior close of $4.44. The stock opened at ...